Skip to main content
Journal cover image

Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects.

Publication ,  Journal Article
Dvergsten, JA; Reed, AM; Landerman, L; Pisetsky, DS; Ilkayeva, O; Huffman, KM
Published in: Rheumatology (Oxford)
April 11, 2022

OBJECTIVES: To perform an exploratory study to identify a JDM serum metabolic profile that differs from healthy controls (HCs) and responds to immunosuppressive treatment. METHODS: Blood was collected from 9 HCs and 10 patients diagnosed with probable (n = 4) or definite (n = 6) JDM based on the criteria of Bohan and Peter for myositis, with 7 of the 10 providing longitudinal samples following initiation of treatment; these patients comprised the treatment-naïve cohort. Sera underwent mass spectroscopy-based measurements of targeted metabolic intermediates, including 15 amino acids, 45 acylcarnitines (ACs), 15 ceramides and 29 sphingomyelins. Principal components analysis reduced metabolites into smaller sets of factors each comprised of correlated metabolic intermediates. Factor scores and metabolite concentrations were compared with HCs using two-sample t-tests while treatment effects were evaluated using paired t-tests. RESULTS: Of eight principal components analysis-derived metabolite factors (one AC, two amino acids, three sphingosine and two ceramide), two were significantly associated with JDM: one AC factor containing mostly long-chain ACs (P = 0.049) and one ceramide factor (P < 0.01). For 12 individual ACs, mostly long chain, and three ceramides, concentrations were significantly greater for JDM than HCs. Factors based on these individual metabolites showed decreasing scores with treatment (P = 0.03 and P < 0.01, respectively). CONCLUSION: While additional validation is needed, these lipids have potential as JDM serum diagnostic and/or treatment biomarkers. Additionally, the significant association of long-chain ACs and ceramides with JDM offers insights regarding pathogenesis, implicating dysregulation of mitochondrial fatty acid β-oxidation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

April 11, 2022

Volume

61

Issue

4

Start / End Page

1699 / 1708

Location

England

Related Subject Headings

  • Metabolomics
  • Lipidomics
  • Humans
  • Dermatomyositis
  • Ceramides
  • Autoantibodies
  • Arthritis & Rheumatology
  • Amino Acids
  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dvergsten, J. A., Reed, A. M., Landerman, L., Pisetsky, D. S., Ilkayeva, O., & Huffman, K. M. (2022). Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects. Rheumatology (Oxford), 61(4), 1699–1708. https://doi.org/10.1093/rheumatology/keab520
Dvergsten, Jeffrey A., Ann M. Reed, Lawrence Landerman, David S. Pisetsky, Olga Ilkayeva, and Kim M. Huffman. “Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects.Rheumatology (Oxford) 61, no. 4 (April 11, 2022): 1699–1708. https://doi.org/10.1093/rheumatology/keab520.
Dvergsten JA, Reed AM, Landerman L, Pisetsky DS, Ilkayeva O, Huffman KM. Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects. Rheumatology (Oxford). 2022 Apr 11;61(4):1699–708.
Dvergsten, Jeffrey A., et al. “Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects.Rheumatology (Oxford), vol. 61, no. 4, Apr. 2022, pp. 1699–708. Pubmed, doi:10.1093/rheumatology/keab520.
Dvergsten JA, Reed AM, Landerman L, Pisetsky DS, Ilkayeva O, Huffman KM. Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects. Rheumatology (Oxford). 2022 Apr 11;61(4):1699–1708.
Journal cover image

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

April 11, 2022

Volume

61

Issue

4

Start / End Page

1699 / 1708

Location

England

Related Subject Headings

  • Metabolomics
  • Lipidomics
  • Humans
  • Dermatomyositis
  • Ceramides
  • Autoantibodies
  • Arthritis & Rheumatology
  • Amino Acids
  • 3204 Immunology
  • 3202 Clinical sciences